PD-L1 Status and Survival in Patients With Lung Cancer

To the Editor As part of a study using clinical data linked to comprehensive genomic profiling results obtained from routine care, Dr Singal and colleagues explored programmed death-ligand 1 (PD-L1) status and clinical outcomes among patients with non –small cell lung cancer (NSCLC) who received anti–programmed cell death protein 1 (PD-1)/PD-L1 therapy. They found that PD-L1 status (negative vs positive; 50% staining as cutoff) was not related to overall survival, regardless of treatment line. However, patients receiving different treatment l ines should be analyzed separately. The KEYNOTE-042 study and KEYNOTE-024 study indicated that the overall survival of patients with NSCLC administered pembrolizumab as first-line therapy was dependent on PD-L1 status.
Source: JAMA - Category: General Medicine Source Type: research